Ritesh Rathore | Profiles RNS

Ritesh Rathore, MD

Associate Professor

Boston University School of Medicine

Dept of Medicine

Hematology & Medical Oncology

MBBS, University College of Medical Sciences

Websites

	Roger Williams Medical Center
	Pubmed

Ritesh Rathore, MD is an Associate Professor of Medicine at Boston University School of Medicine. He specializes in Hematology and Medical Oncology. His clinical and research interests include gastrointestinal cancer, Immunotherapy, head/neck/thoracic cancers and cancer clinical trials. He speaks four languages proficiently: English, Hindi, Bengali and Gujarati.

Roger Williams Medical Center

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Keating MJ, Giscombe L, Tannous T, Reddy N, Mukkamalla SKR, DeSouza A, Rathore R. Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer. J Oncol Pharm Pract. 2019 Dec; 25(8):1927-1932. PMID: 30880568

Thakur A, Rathore R, Kondadasula SV, Uberti JP, Ratanatharathorn V, Lum LG. Immune T cells can transfer and boost anti-breast cancer immunity. Oncoimmunology. 2018; 7(12):e1500672. PMID: 30524893

Reha J, Mukkamalla SKR, Rathore R, Somasundar PS. Adequate lymph node evaluation in the elderly is associated with improved survival in patients with stage I-III colon cancer: A validation study using the National Cancer Data Base. Eur J Surg Oncol. 2018 Jan; 44(1):148-156.View Related Profiles.

Somasundar, Ponnandai
Rathore, Ritesh

PMID: 29198492

Huynh D, Mukkamalla S, Rathore R. Adjuvant therapy for pancreatic cancer: An updated analysis of treatment outcomes in elderly patients using the National Cancer Database (NCDB). Ann Oncol. 2017 Jun; 28 Suppl 3:iii72-iii73. PMID: 32136001

Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS, Cohen SI. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. 2016 Oct; 76(14):1257-70.View Related Profiles.

Cabral, Howard
Rathore, Ritesh

PMID: 27324746; DOI: 10.1002/pros.23214;

Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer. 2015; 2015:285193. PMID: 25802762; PMCID: PMC4352947; DOI: 10.1155/2015/285193;

Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res. 2015 May 15; 21(10):2305-14. PMID: 25688159; PMCID: PMC4433762; DOI: 10.1158/1078-0432.CCR-14-2280;

Birnbaum A, Dipetrillo T, Rathore R, Merriam P, Wanebo H, Thomas A, Puthawala Y, Joyce D, Luppe D, Khurshid H, Follett N, Sio TT, Safran H. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study. Am J Clin Oncol. 2014 Apr; 37(2):162-6. PMID: 23275269; DOI: 10.1097/COC.0b013e31826e06e0;

Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, Colaiace WM, Rathore R. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study. Bone Marrow Transplant. 2014 Jan; 49(1):73-9. PMID: 24056738; PMCID: PMC3891305; DOI: 10.1038/bmt.2013.133;

Ready NE, Rathore R, Johnson TT, Nadeem A, Chougule P, Ruhl C, Radie-Keane K, Theall K, Wanebo HJ, Marcello J, Kennedy T. Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2012 Feb; 35(1):6-12.View Related Profiles.

Wanebo, Harold
Rathore, Ritesh

PMID: 21293244; DOI: 10.1097/COC.0b013e3182019ee3;

Showing 10 of 28 results. Show More

Wanebo HJ, Rathore R, Chougule P, DiSiena MR, Koness RJ, McRae RG, Nigri PT, Radie-Keane K, Ready N. Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. Ann Surg Oncol. 2011 Nov; 18(12):3479-85.View Related Profiles.

Wanebo, Harold
Koness, Robert
Rathore, Ritesh

PMID: 21553142; DOI: 10.1245/s10434-011-1697-0;

Birnbaum A, Dipetrillo T, Rathore R, Anderson E, Wanebo H, Puthwala Y, Joyce D, Safran H, Henderson D, Kennedy T, Ready N, Sio TT. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol. 2010 Apr; 33(2):144-7. PMID: 19786848; DOI: 10.1097/COC.0b013e3181979093;

Rathore R, Birnbaum A, Rathore B, DiPetrillo T, Kennedy T, Ready N. Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93). Cancer Chemother Pharmacol. 2010 Nov; 66(6):1013-7.View Related Profiles.

Rathore, Bharti
Rathore, Ritesh

PMID: 20130878; DOI: 10.1007/s00280-010-1251-y;

Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, Iannitti D, Kennedy T. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol. 2010 Feb; 33(1):43-6. PMID: 19687731; DOI: 10.1097/COC.0b013e31819d8668;

Chougule PB, Akhtar MS, Rathore R, Koness J, McRae R, Nigri P, Radie-Keane K, Kennedy T, Wanebo HJ, Ready N. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53). Head Neck. 2008 Mar; 30(3):289-96.View Related Profiles.

Wanebo, Harold
Koness, Robert
Rathore, Ritesh

PMID: 17657799

Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006 Jan 1; 12(1):183-90. PMID: 16397041

Tsai JY, Iannitti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K, Safran H. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. Am J Clin Oncol. 2005 Aug; 28(4):329-33. PMID: 16062072

Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY, Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004; 22(5):706-12. PMID: 15581051

Safran H, DiPetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R, Wanebo H, Hughes M, Maia C, Tsai JY, Pasquariello T, Pepperell JR, Cioffi W, Kennedy T, Reeder L, Ng T, Adrian A, Goldstein L, Chak B, Choy H. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest. 2004; 22(5):670-7.View Related Profiles.

Wanebo, Harold
Rathore, Ritesh

PMID: 15581047

Lum LG, Rathore R, Quesenberry PJ, Elfenbein GJ. Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells. Med Health R I. 2003 Aug; 86(8):247-8. PMID: 14582220

Rathore R, Elfenbein GJ. The chronic leukemias: current and novel therapeutic approaches. Med Health R I. 2003 Aug; 86(8):240-2. PMID: 14582218

Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ. Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells. Clin Breast Cancer. 2003 Aug; 4(3):212-7. PMID: 14499016

Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T. A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer. 2002 Nov 1; 95(9):2000-5. PMID: 12404295

Safran H, Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Crit Rev Oncol Hematol. 2002 Jul; 43(1):57-62. PMID: 12098607

Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, Berzein K, Moore T, Iannitti D, Reiss P, Pasquariello T, Akerman P, Quirk D, Mass R, Goldstein L, Tantravahi U. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol. 2001 Oct; 24(5):496-9. PMID: 11586103

Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, Harrington D, Quirk D, Rathore R, Cruff D, Vakharia J, Vora S, Savarese D, Wanebo H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001 Apr 1; 49(5):1275-9.View Related Profiles.

Wanebo, Harold
Rathore, Ritesh

PMID: 11286834

Butera J, Malachovsky M, Rathore R, Safran H. Novel approaches in development for the treatment of pancreatic cancer. Front Biosci. 1998 Nov 1; 3:E226-9. PMID: 9792896

Fata F, Rathore R, Schiff C, Herzlich BC. Bronchiolitis obliterans organizing pneumonia as the first manifestation of polymyositis. South Med J. 1997 Feb; 90(2):227-30. PMID: 9042178

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 28 publications over 19 distinct years, with a maximum of 3 publications in 2003 and 2010

Bar chart showing 28 publications over 19 distinct years, with a maximum of 3 publications in 2003 and 2010

Year	Publications
1997	1
1998	1
2001	2
2002	2
2003	3
2004	2
2005	1
2006	1
2008	1
2010	3
2011	1
2012	1
2013	1
2014	1
2015	2
2016	1
2017	2
2018	1
2019	1

Contact for Mentoring:

25 Buick St
Boston MA 02215
Google Map

401.456.2077

Download vCard

Rathore's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (136) concept(s)

Co-Authors

See all (5) people

Similar People

See all (60) people

Same Department

Search Department